Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Articles
BioCentury
|
Apr 28, 2008
Clinical News
Neu2000KL: Phase I final data
...up to 6,000 mg of Neu2000KL were well tolerated. There were no serious adverse events.
Amkor Pharma Inc.
...
Read More
BioCentury
|
Apr 3, 2008
Distillery Therapeutics
This Week in Therapeutics
...progression or prominent axonal loss in the spinal cord. Researchers did not disclose next steps.
Amkor Pharma Inc.
's...
Read More
Items per page:
10
1 - 2 of 2
BioCentury
|
Apr 28, 2008
Clinical News
Neu2000KL: Phase I final data
...up to 6,000 mg of Neu2000KL were well tolerated. There were no serious adverse events.
Amkor Pharma Inc.
...
Read More
BioCentury
|
Apr 3, 2008
Distillery Therapeutics
This Week in Therapeutics
...progression or prominent axonal loss in the spinal cord. Researchers did not disclose next steps.
Amkor Pharma Inc.
's...
Read More
Items per page:
10
1 - 2 of 2
Previous page
Next page